The quantitative measurement of biomarkers is central to the pharmacodynamic assessment of drug candidates during pharmaceutical development and also in clinical disease management (1, 2 ) . Protein biomarkers constitute a major focus within this field, and analytical modalities for their measurement are evolving and maturing. Liquid chromatography/tandem mass spectrometry (LC-MS/MS) 4 is a key technology that has been explored in recent years for protein biomarker quantification (3 ) . Most published approaches measure 1 or several peptides, which are enzymatically released from the target protein of interest as part of the assay procedure; quantification is typically based on molar equivalency between the surrogate peptide and protein.
Hybrid immunoaffinity-mass spectrometric methods have been developed to address the detection-limit challenges associated with measuring low-abundance protein biomarkers in the low-and sub-g/L range (4, 5 ) . Antibody capture can be at either protein or peptide level. The most appropriate approach for achieving the analytical aim depends on a multitude of factors, including reagent availability, existing sample preparation platforms, throughput requirements, and the follow-up method for biomarker quantification (4 ) . A promising immunoaffinity strategy for protein biomarker quantification is termed stable isotope standards and capture by antipeptide antibodies (SISCAPA) (6 ) . This strategy includes enrichment of an enzymatically derived peptide and its synthetic stable isotope-labeled (SIL) analog using an antipeptide antibody followed by LC-MS/MS detection, executed mostly with selected reaction monitoring (SRM) mass spectrometry.
A number of different magnetic-bead and flowbased SISCAPA assay formats have been explored. Although the original SISCAPA work relied on online nanoliter immunoaffinity columns based on Poros supports linked to nanoflow LC and nanospray mass spectrometry (6 ) , off-line magnetic bead-based enrichment of enzymatically released peptides followed by either nano-or capillary LC-MS/MS has become a popular approach (7) (8) (9) (10) (11) (12) . Bead-based sample preparation has the advantage that the antibody capture step can be done in parallel for multiple samples, and this process can be automated on a magnetic particle processor (11 ) or liquid-handling robotics, as shown for immunoaffinity enrichment of proteins (13, 14 ) . An extension of the magnetic bead SISCAPA work is the use of an inline bead-trap device to allow the quantification of lower-abundance peptides in a more automated fashion and with reduced off-line handling (15 ) . Using a different combination of chromatography and mass spectrometry modalities, other groups have focused their efforts on hyphenating relatively largecapacity, high-flow peptide immunoaffinity chromatography online with conventional LC-MS/MS (16 -18 ) . Assays based on this technology have been validated for clinical use and show the robustness/ruggedness required for routine implementation in clinical protein biomarker investigations (19 ) . Depending on the antibody and relevant assay parameters, the peptide immunoaffinity columns can be used for hundreds to a few thousand runs, contributing to overall robustness.
We report here an online immunoaffinity LC-MS/MS configuration that combines high-flow peptide immunoaffinity enrichment and nanoflow LC-MS/MS. We validated this approach by developing an assay for salivary pepsin/pepsinogen, which has been reported to be detectable in the saliva of some patients with gastroesophageal reflux disease (GERD), and which correlates with proximal reflux episodes, detected using 24-h pHmetry (20 ) .
Materials and Methods

MATERIALS
We obtained human pepsinogen A (UniProtKB P00790; 40.3 kDa) lyophilized ELISA standards from Epitope Diagnostics. We used 2 standards that, upon reconstitution, gave concentrations of 300 g/L with 10% BSA carrier and 3000 g/L with 2% BSA in PBS and thiomersal (0.045%). Standard concentrations were assigned by micro bicinchoninic acid assay. We obtained the following synthetic peptide standards from Thermo Biopolymers: unlabeled (light) DRANNQVGLAPVA and labeled (heavy) D(R)(A)NNQVGLAPVA (mass increments, A plus 4 Da and R plus 10 Da; isotope purity of labeled amino acids was 99%). There was no detectable interference at the mass of the unlabeled (light) peptide, at m/z 1324.6, stemming from the stable isotope labeled peptide as confirmed by a MALDI mass spectrum (see Supplemental Data 1, which accompanies the online version of this article at http://www.clinchem.org/vol56/issue9). For the calculation of concentrations, we considered peptide purity (Ͼ97% by HPLC) and peptide net content determined by amino acid analysis. We purchased sequencing-grade endoprotease Asp-N from Roche Diagnostics. Affinity-purified polyclonal antipeptide antibody, custom-generated in rabbits immunized with DRANNQVGLAPVA, was obtained from Lampire Biological Laboratories. The immunogen peptide (Ͼ95% purity) was of identical sequence to the analyte peptide and was conjugated to keyhole limpet hemocyanin (KLH) via an additional N-terminal cysteine (CGG-DRANNQVGLAPVA; GG added as spacer). Saliva samples were from in-house collections and Bioreclamation. The volunteers provided written informed consent, and the study was carried out in accordance with the Helsinki Declaration of 1975, as revised in 1983. Samples were primarily from presumed healthy volunteers and, in some cases, contained multiple samples from the same subject. Chemicals such as Tris-HCl, sodium acetate, sodium phosphate, sodium chloride, sodium azide, phosphate buffered saline, ethanolamine, and ammonium bicarbonate were from Sigma-Aldrich. We obtained analytical reagent-grade triethanolamine from Fisher and purchased the bicinchoninic acid protein assay and dimethyl pimelimidate HCl from Pierce (Perbio Science UK Ltd.). Self-Pack Poros 20G Protein G beads (particle size 20 m) were from Applied Biosystems.
We built immunoaffinity columns in-house according to the manufacturer's instructions and akin to procedures described for the same capture phase (18 ) or for similar capture phases (16, 17 ) . A detailed procedure can be found in online Supplemental Data 2.
LC CONFIGURATION
The peptides obtained from total saliva digests were separated by using an Ultimate 3000 capillary HPLC system (LC Packings, Dionex) consisting of a SRD-3600 solvent rack with integrated vacuum degasser, a LPG-3600M quaternary low-pressure gradient pump, a FLM-3100 flow manager with thermostatted column compartment set to 30°C, and a FLM-3200 flow manager with thermostatted column compartment set to 60°C. The FLM-3100 module housed a 2-way 10-port switching valve, whereas the FLM-3200 module housed a 2-way 10-port switching valve and a 2-way 6-port switching valve. Two dual low-pressure gradient pumps were accommodated in a DGP-3600M module, and a WPS-3000 thermostatted well plate autosampler set to 8°C was fitted with a 250-L syringe and a 250-L injection loop. The system was controlled by Chromeleon software 6.8.
The system used 3 pumps ( Fig. 1 ): a loading pump connected to the antipeptide antibody column, Micro Pump 1 supplying the analytical column with nanoflow rates, and Micro Pump 2 washing and equilibrating the reversed-phase trap cartridge.
For this LC configuration to function appropriately using the below flow rates, the internal dimensions of connecting tubing is important. All connections into valve A and from valve A to valve B were 250 m in diameter and thus suitable for higher flow rates, but the tubing from valve B to valve C was 100 m in diameter and approximately 30 cm in length. The reversed-phase trap cartridge was connected into valve C using 50-m-diameter PEEKsil tubing at 5-and 10-cm length. The analytical column was connected into valve C using a 30-cm long piece of fused silica tubing with an internal diameter of 20 m.
The antibody column was equilibrated during the injection cycle with 25 mmol/L ammonium formate (AF), pH 7.0, at 0.3 mL/min with valve A in position 1 and valve B in position 2. A sample volume of 230 L was loaded for 3 min using the same buffer and flow rate. Whereas the target peptide and its SIL analog were retained on the antibody column, other components of the sample were washed through to waste. Additional washing was achieved from 3 to 6.5 min at a flow rate of 0.6 mL/min. The flow rate was then returned to 0.3 mL/min and valve B and valve C were switched to position 1 before the loading pump solvent composition was changed to 0.2% formic acid. The eluent containing the target peptides was collected on a PepMap100 C18 cartridge (5 by 0.3 mm, 5 m, 120 Å, Dionex) for 3.5 min (8.75-12.25 min) at 0.3 mL/min. The antibody column was then washed for 1 min with 0.2% formic acid at 1.2 mL/min followed by a 0.5-min wash with 2% formic acid and 3% ethanol. At the end of the chromatography cycle (after 15 min), the antibody column was returned to the starting conditions (25 mmol/L AF, 0.3 mL/min). Meanwhile, the target peptide and SIL analog were back-eluted from the C18 trap onto a PepMap100 C18 analytical nanocolumn (5 cm by 75 m, 3 m, 100 Å, Dionex) at a flow rate of 400 nL/min. The mobile phases were 0.1% formic acid in 2% ACN (solvent A) and 0.1% formic acid in 90% ACN (solvent B), and the gradient started from 5% B at 10 min to 30% B at 15 min.
To minimize any carryover originating from the reversed-phase trap cartridge, a wash solution contain-ing 0.1% formic acid, 25% isopropanol, and 50% acetonitrile was supplied by Micro Pump 2 at 150 L/mL from 1.5 to 3.5 min run time (valve B position 2, valve C position 1). Subsequently, the trap was equilibrated with solvent A at a flow of 150 L/mL before receiving the eluent from the antibody column.
For evaluation of system suitability, the antibody column can also be bypassed (valve A position 2, valve B position 1, valve C position 1) to load a standard peptide directly onto the reversed-phase trap column. Comparing the SRM response to that of the same standard sample analyzed through the antibody enrichment pathway enabled establishing the capture efficiency of the antibody column.
MASS SPECTROMETRY
We operated a 4000 Qtrap mass spectrometer (Applied Biosystems) with a Nanospray II interface (MDS Sciex) and Analyst software version 1.5. We used a stainless steel emitter (50 mm by 30 m ID, Proxeon) together with the following source conditions: ion spray voltage 4000 V, nebulizing gas 12, curtain gas 15, interface heater temperature 180°C. Two SRM transitions were recorded for both the doubly charged native and SIL peptide: Q1 662. ). The dwell time was 200 ms, collision energy was set to 27 V, and Q1 and Q3 were operated in low resolution. Other relevant instrument settings: declustering potential 75 V, entrance potential 10 V, and collision cell exit potential 9 V.
DATA PROCESSING FOR QUANTIFICATION
We used the 662.85 [Mϩ2H] 2ϩ to 1039.53 (b 10 ϩ ) and 669.85 [Mϩ2H] 2ϩ to 1053.53 (b 10 ϩ ) SRM transitions for native and SIL peptide, respectively, for quantification. We established signal area ratios between native and SIL peptides and calculated absolute amounts of detected native peptide (fmol) by multiplication of the area ratio by 2 fmol (amount of SIL standard added). Standard curves were obtained by plotting total quantity of detected pepsinogen-derived peptide (fmol) against the pepsinogen concentration calculating a weighted (1/y 2 ) multiparameter curve fit in Labstats (Excel add-in). We evaluated the quality of the curve fit by back-calculating pepsinogen concentrations of calibrants. Molar pepsin/pepsinogen concentrations reported throughout are derived from backcalculation using the calibration curves. Measurements of total pepsin/pepsinogen concentration are based on molar equivalency between the surrogate peptide and protein. Scalability of analyte response with sample volume. We prepared pepsinogen standard curves in a blank human saliva pool using the 7.44 nmol/L (300 g/L) pepsinogen stock. We prepared serial dilutions with concentrations ranging from 19.3 to 1240 pmol/L (0.78 -50 g/L) and processed duplicate samples of 5, 10, 15, and 20 L as described above. All reagent volumes and concentrations remained unchanged with the exception of Asp-N, whose concentration was scaled according to the total salivary protein amount per sample while maintaining an enzyme-to-protein ratio of 1:150.
Experiments investigating the effect of carrier protein in the pepsinogen standard preparation and the influence of increasing Asp-N amounts on the assay outcome are described in online Supplemental Data 2.
ASSAY VALIDATION
The final sample preparation methodology was as follows. Human saliva samples were centrifuged for 10 min at 4°C and 21 000g, and the supernatant was transferred to a 96-well plate. To each sample, we added 100 L of 20 mmol/L ammonium bicarbonate, pH 7.9, and 20 L of 100 amol/L SIL peptide D(*R)(*A)NNQVGLAPVA. The samples were heated to 100°C for 25 min and the plate was then allowed to cool to room temperature before adding 80 L of 68% acetonitrile together with 62.5 L of 2 ng/L Asp-N in 10 mmol/L Tris-HCl, pH 7.5. The samples were incubated for 16 We investigated dilution linearity using a 744 pmol/L (30 g/L) pepsinogen spike in saliva. Triplicate samples after 2-, 5-, and 10-fold dilution with 20 mmol/L ammonium bicarbonate, pH 7.9, were analyzed alongside the corresponding undiluted preparation.
Benchtop stability of saliva samples containing a 198 pmol/L (8.0 g/L) pepsinogen spike was investigated at room temperature and at approximately 4°C for 1, 2, 4, and 8 h. Freeze-thaw stability was assessed for up to 3 cycles also using the 198 pmol/L (8.0 g/L) pepsinogen spike.
Results and Discussion
LIQUID CHROMATOGRAPHY CONFIGURATION
This assay was configured to achieve the following performance characteristics:
1. The implementation of a high-capacity antipeptide antibody stationary phase maximizes capture efficiency, ensures robustness, ease of use, and other characteristics while the connection with nanoflow chromatography maintains the sensitivity advantages associated with nanospray ionization. 2. Enabled by high-capacity immunoaffinity enrichment without compromising performance, the injection volume of this methodology can be varied and ranges from low microliters to 1 milliliter. In this way, sensitivity is scalable with injection volume; and different assay sensitivity requirements can be accommodated with the same chromatography configuration. 3. As a consequence of the antibody cleanup step, the sample complexity is reduced substantially and contributes to a reduced burden on the nanochromatography components, most notably the analytical column as well as the nanospray emitter. The result is increased assay robustness because these parts need to be maintained or changed less frequently. 4 . Peptide mixtures that elute from the antibody column are relatively simple; thus, extensive reversedphase chromatography is typically not required. In the configuration described herein, the entire chromatographic cycle, including antibody enrichment, lasted 15 min. These methods enable the analysis of hundreds of samples within an acceptable time frame; for example, an entire 96-well plate can be analyzed in little more than 24 h. 5. The sample cleanup facilitated through the antipeptide antibody enrichment step provides an additional optimization opportunity. It can be explored if the overall assay sensitivity can be boosted by widening the quadrupole resolution (Q1 and Q3) from unit to low, like in this case, while ensuring that noise does not increase concomitantly and no other SRM signals interfere with measurement.
A limitation for setting up such an assay may be the time required and likelihood of success in generating an antipeptide antibody. An approach that has proven to be successful is raising rabbit polyclonal antipeptide antibodies. Although this can be achieved rapidly, in some cases taking as little as 2 to 3 months, the process may also take much longer and one has to recognize the risk that an antigenic response in animals may not be achieved. In the case presented herein, a useable amount of affinity-purified antibody (Ն1 mg) was available approximately 10 weeks after project initiation, and larger quantities were available approximately 2 months later for longer-term use. Other capture modalities or antibody types, such as monoclonal antibodies, which have become popular for SISCAPA applications not only because of their better long-term supply (10, 21 ) , can be equally applied if available.
To ensure robust nanospray performance, this method used a stainless steel nanospray emitter, tapered in the outer diameter only, to avoid clogging and other drawbacks associated with other types of nanospray emitters (22 ) . Achievable raw mass spectrometric detection limits are comparable to fused silicabased nanospray emitters (23 ), and we typically observe unchanged performance without any intervention often beyond 2 weeks of unattended and continuous operation. We have successfully used this emitter in other quantitative investigations (13, 24 ) .
SELECTION OF TARGET PEPTIDE
Pepsinogen is produced in gastric chief cells and secreted into the lumen of gastric glands, where an acidmediated self-activation results in the release of a propeptide and generation of active pepsin. Pepsin is characterized by a low isoelectric point (pI) value of 3.4 (http://www.expasy.org/tools/pi_tool.html). It contains only 3 basic amino acids (3 arginine; no lysine) but 35 acidic amino acids (21 aspartic acid; 14 glutamic acid). A trypsin digestion would generate only a few potentially useful peptides for SRM detection. Extending the assay to measure simultaneously a propeptidederived tryptic peptide could be challenging because of the lack of suitably sized fragments. In contrast, a digestion with endoproteinase Asp-N, taking advantage of the higher abundance of aspartic acids in pepsinogen, yields a number of potential target peptides for an SRM assay.
This work targets the Asp-N-derived C-terminal fragment DRANNQVGLAPVA providing a combined measurement of pepsin and pepsinogen. The presence of an arginine in the target sequence contributes to good ionization efficiency of this peptide. An MS/MS spectrum of DRANNQVGLAPVA with annotation of main fragments is shown in online Supplemental Data 3. High mass fragments b 10 ϩ and b 9 ϩ (m/z above the precursor) were used for developing SRM transitions, and a BLAST search (http://blast.ncbi.nlm.nih.gov/ Blast.cgi) confirmed that this peptide exclusively occurs in human pepsin/pepsinogen. We selected the Asp-N digestion strategy also because it creates the possibility to extend assay development (beyond what is described here) to DFLKKHNLNPARKYFPQWEAPTLV. A possible simultaneous measurement of this peptide spanning the propeptide and the mature pepsin sequence would indicate the presence of salivary pepsinogen as opposed to the clipped propeptide generated in the stomach. In this study, human pepsinogen was used for method development and validation, but assay performance using the mature pepsin is anticipated to be similar, because the target sequence is located in the accessible C-terminal portion of the protein.
ASSAY DEVELOPMENT
The final developed work flow for the pepsin/pepsinogen assay is shown in Fig. 2 . All experiments were performed with a pool of human saliva, where pepsin/ pepsinogen concentrations were undetectable.
Heat inactivation of proteolytic activity in saliva.
Human saliva contains an arsenal of enzymes such as glycosidases and peptidases (25, 26 ) . This enzymatic activity needs to be quenched to ensure target peptide stability under the conditions used for sample processing, such as the overnight digestion at 37°C. In the method optimization experiment where saliva samples were heattreated at different temperatures and durations to find appropriate conditions for protein denaturation and inactivation of remaining salivary enzymatic activity, pretreatment at 37 and 50°C for up to 60 min resulted in complete loss of the target peptide in saliva (Fig. 3) , and heating at 60°C for 60 min began to show a marginal improvement in recovery of approximately 10%. In contrast, heat pretreatment at 70 and 80°C demonstrated a larger effect of time-dependent inactivation of salivary enzymes and hence improved recovery. Heating saliva up to 90°C improved recovery further beyond 80% after 20 min of treatment, but it was not before heat treatment at approximately 100°C for at least 20 min that near 100% target peptide recovery was achieved.
As a result, a 25-min heat treatment at 100°C was incorporated into the assay to ensure that an overnight Asp-N digestion would be possible without significant loss of target peptide. A control experiment demonstrated that target peptide recovery from a saliva sam- ple spiked with pepsinogen before heat treatment was 108% compared with a saliva sample analyzed alongside where the pepsinogen spiking occurred after heat pretreatment. This illustrated that heat inactivation does not introduce losses of target peptide. This kind of heat inactivation provides a unique advantage to this LC-MS/MS measurement at peptide level and is likely to be impractical for stabilizing the analyte signal before immunoassay analysis.
Scalability of analyte response with sample volume. The analyte response obtained from different saliva volumes containing serial dilutions of pepsinogen from 1240 to 19.3 pmol/L in a blank saliva pool is shown in Fig. 4 . With the exception of the lower end of the 5-L curve, which approaches the limit of detection of the assay, parallel curves were generated from different saliva volumes. Thus the assay can be scaled with sample volume to obtain the desired working range. It is expected that assay detection limits can be boosted further by increasing the saliva volume beyond 20 L, taking advantage of the large specific binding capacity of the antipeptide antibody column.
Effect of carrier protein in pepsinogen standard preparation. Although linear at lower pepsinogen concentrations, standard curves in a 20-L saliva pool prepared from a 300 g/L pepsinogen stock containing 10% (wt/ vol) BSA gave a nonlinear analyte response at the top end of the curve, i.e., Ͼ600 pmol/L (see online Supplemental Data 4). The amount of carrier protein altered the Asp-N to total protein ratio and affected Asp-N digestion efficiency. As a consequence, a higher concentrated pepsinogen stock solution (3000 g/L) containing a lower amount of BSA carrier [2% (wt/vol)] was custom-prepared and resulted in linear standard curves across the entire calibration range.
Total salivary protein vs amount of Asp-N.
A single Asp-N-mediated cleavage of pepsinogen affords the targeted peptide. We investigated a number of buffer systems to optimize digestion efficiency (data not shown); 10 mmol/L ammonium bicarbonate, pH 7.9, containing 20% acetonitrile yielded the highest response. Reduction and alkylation did not improve efficiency further and were omitted from the final assay procedure. The protein concentration in the human saliva pool was determined to be approximately 2.5 g/L, which falls within the normal range typically observed (27, 28 ) . This formed the basis for preparing test samples with varying enzyme-to-total salivary protein ratios also containing a 372 pmol/L (15 g/L) pepsinogen spike. Analyte responses upon Asp-N digestion are shown in online Supplemental Data 5, and as a result, a 1:400 Asp-N to total salivary protein ratio was selected for further assay development and validation.
FIT-FOR-PURPOSE ASSAY VALIDATION
Calibration matrix and calibration curve. Assay validation using a fit-for-purpose approach has been described and is used widely for biomarker assays (29 ) . Performing assay calibration in the same matrix as the study samples that are to be tested poses a challenge for biomarker assays where the analyte is endogenous and analyte-free matrix is not easily available. In the current case, the target analyte pepsinogen is not typically present in detectable quantities in saliva, thus analytefree saliva matrix is relatively easy to obtain. Therefore, a pool of human saliva in which pepsin/pepsinogen could not be detected was chosen as the matrix for assay calibration and quality control.
The calibration curves obtained on each testing occasion during assay validation are shown in Fig. 5 . The calibration was modeled using a multiparameter curve fit and a weighting factor of 1/y 2 . Slopes of the curves ranged from 0.95 to 0.97. The quality of the curve fits was assessed by back-calculating calibrant concentrations (see online Supplemental Data 6). The resulting RE was from Ϫ1.1% to 1.4%. Interassay imprecision of the overall mean of all calibration standards of all curves ranged between 4.6% and 13.1% CV.
Imprecision and inaccuracy. Intra-and interassay imprecision and inaccuracy of the validation samples are presented in Table 1 . Assessment of intraassay imprecision at each validation sample concentration using 6 replicates ranged from 5.0% to 14.1% CV and from 10.35 to 14.7% CV at the lowest concentration. Intraassay inaccuracies ranged from Ϫ2.9% to Ϫ15.9% and from 2.0% to 17.6% at the lowest level. The interassay imprecision was 6.2%-14.0% CV, and the interassay inaccuracy was between Ϫ1.2 and Ϫ14.9% at all concentrations. All assay validation results were found to be within the 20% preset acceptance criteria, demon- The calibration was modeled against a weighting factor of 1/y 2 . strating that this assay is precise and accurate. Based on observed performance and signal-to-noise ratio (S/N) at 4.08 pmol/L (average S/N of all lowest calibrants during validation was 10.1), the assay was found to be capable of quantification at this concentration. Representative SRM traces obtained from a series of samples containing both pepsin C-terminal peptide and SIL standard are presented in Fig. 6 . The extracted ion chromatograms from the 2 low validation samples at 7.4 and 24.8 pmol/L pepsinogen are shown in Fig. 6a and b. Carryover. As reported by Li et al. (19 ) , the main source for carryover in a peptide immunoaffinity chromatographic assay is the antibody column. Absolute carryover was typically between 0.7% and 0.9% as determined by a blank run directly after the highest calibration standard.
Dilution. We tested dilution linearity using a 744 pmol/L (30 g/L) pepsinogen spike in a human saliva pool after 2-, 5-, and 10-fold dilution with 20 mmol/L ammonium bicarbonate, pH 7.9 (each n ϭ 3). Compared to an undiluted sample, interpolated to 764 pmol/L pepsinogen (n ϭ 3; 2.8% CV, 2.7% RE), the diluted saliva samples gave the following results: 2-fold dilution 817 pmol/L pepsinogen (n ϭ 3; 3.8% CV; 6.9% RE), 5-fold dilution 768 pmol/L pepsinogen (n ϭ 3; 18.7% CV; 0.5% RE), and 10-fold dilution 854 pmol/L pepsinogen (n ϭ 3; 6.4% CV; 11.8% RE). Results demonstrated that up to 10-fold dilution of human saliva samples would be acceptable if required.
Stability. Pepsinogen spiked at 198 pmol/L in a human saliva pool was found to be stable to 1, 2, and 3 freeze/ thaw cycles. Measured values from triplicate analyses deviated by Ϫ7.7%, Ϫ3.4%, and Ϫ5.2%, respectively, from a fresh preparation (177 pmol/L interpolated pepsinogen; Ϫ10.3% RE) that did not undergo any freeze/thaw event. Imprecision in all preparations ranged from 2.4% to 7.8%.
We evaluated benchtop stability of pepsinogen spiked at 198 pmol/L (8.0 g/L) into unprocessed human saliva at room temperature and at approximately 4°C for 1, 2, 4, and 8 h. Compared with a fresh preparation (interpolated at 176 pmol/L pepsinogen, n ϭ 3; 5.0% CV; Ϫ11.8% RE), the following results were obtained for room temperature stability: 1 h, 174 pmol/L pepsinogen (n ϭ 3; 3.7% CV; 0.3% RE); 2 h, 184 pmol/L pepsinogen (n ϭ 3; 4.5% CV; 5.5% RE); 4 h, 173 pmol/L pepsinogen (n ϭ 3; 13.1% CV; Ϫ0.7% RE); and 8 h, 167 pmol/L pepsinogen (n ϭ 3; 1.6% CV; Ϫ4.5% RE). Short-term storage stability at approximately 4°C was as follows: 1 h, 170 pmol/L pepsinogen (n ϭ 3; 1.4% CV; Ϫ2.8% RE); 2 h, 177 pmol/L pepsinogen (n ϭ 3; 5.2% CV; 1.3% RE); 4 h, 162 pmol/L pepsinogen (n ϭ 3; 0.4% CV; Ϫ7.4% RE); and 8 h, 161 pmol/L pepsinogen (n ϭ 3; 8.8% CV; Ϫ8.0% RE). As a result, benchtop stability was confirmed for up to 8 h at room temperature and approximately 4°C in a spiked saliva pool.
APPLICATION OF METHOD FOR ANALYSIS OF SALIVA
We tested a number of saliva samples from presumed healthy volunteers (n ϭ 50) for pepsin/pepsinogen concentrations to begin evaluating the immunoaffinity LC-MS/MS platform. The analyte response for most of the saliva samples was below the lower limit of quantification of 4.08 pmol/L (78% of all samples). An extracted ion chromatogram from a representative saliva sample that contained no detectable amount of the human pepsin C-terminal peptide but the SIL peptide is shown in Fig. 6c . The detection of salivary pepsin/pepsinogen was not expected from normal healthy volunteers; however, positive results were observed in 22% of the samples. Low but quantifiable signals derived from the pepsin C-terminal peptide were recorded ranging from 4.3 to 16.6 pmol/L (0.17-0.67 g/L) total salivary pepsin/pepsinogen. For example, Fig. 6d and 6e show extracted ion chromatograms of saliva samples with detectable pepsin C-terminal peptide at 4.9 and 5.2 pmol/L, respectively. The detection of some total salivary pepsin/pepsinogen in a presumed healthy population is surprising and is anticipated to prompt a larger dedicated investigation of salivary concentrations in normal healthy volunteers and in GERD patients using this assay. Further investigations beyond this initial technical report can explore if measured pepsin/pepsinogen concentrations should be normalized against total salivary protein concentration or other consistently observed parameters. However, it is conceivable that concentrations are not linked to salivary protein content, because proximal reflux and regurgitation is believed to be the cause for the presence of pepsin/pepsinogen in saliva as opposed to normal salivary secretion.
Conclusions
We have illustrated the performance of a novel highflow peptide immunoaffinity enrichment and nanoflow LC-MS/MS assay as a high-sensitivity platform for protein bioanalysis in the low-picomolar range. Assay throughput, robustness, and other performance characteristics were found to be compatible with expectations for clinical sample analysis. Besides its quantitative attributes, this methodology is also characterized by high measurement specificity and selectivity, providing increased qualitative confidence of low-level pepsin/pepsinogen detections compared with traditional immunoanalytical approaches.
Previous methodologies for the detection of pepsin have lacked the validation of the present assay and may have underestimated its presence. This assay will now allow us to understand the true prevalence of proximal esophageal reflux and regurgitation in healthy and patient populations to better understand the correlation between the presence of salivary pepsin/ pepsinogen and patients' experience of typical GERD symptoms such as heartburn and regurgitation. This assay could prove useful in the development of new therapies for these conditions.
